130 related articles for article (PubMed ID: 26845992)
1. [Treatments of chronic hepatitis B aiming to HBs seroclearance].
Tsuge M; Chayama K
Nihon Rinsho; 2015 Dec; 73 Suppl 9():535-9. PubMed ID: 26845992
[No Abstract] [Full Text] [Related]
2. Hepatitis B surface antigen seroclearance in patients with chronic hepatitis B infection: a clinical study.
Ruan P; Xu SY; Zhou BP; Huang J; Gong ZJ
J Int Med Res; 2013 Oct; 41(5):1732-9. PubMed ID: 23908397
[TBL] [Abstract][Full Text] [Related]
3. In vitro use of autologous dendritic cells improves detection of T cell responses to hepatitis B virus (HBV) antigens.
Carotenuto P; Artsen A; Niesters HG; Osterhaus AD; Pontesilli O
J Med Virol; 2009 Feb; 81(2):332-9. PubMed ID: 19107973
[TBL] [Abstract][Full Text] [Related]
4. [Hepatitis B virus e antigen plays an important role in the treatment for chronic hepatitis B].
Kanda T; Nakamoto S; Sasaki R; Wu S
Nihon Rinsho; 2015 Dec; 73 Suppl 9():531-4. PubMed ID: 26845991
[No Abstract] [Full Text] [Related]
5. Sequential combination therapy for chronic hepatitis B: more challenges to be tackled.
Tseng TC; Liu CJ; Kao JH
Am J Gastroenterol; 2007 Jul; 102(7):1544; author reply 1545. PubMed ID: 17593169
[No Abstract] [Full Text] [Related]
6. [Management of HBeAg negative chronic hepatitis B].
Jia JD
Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):539. PubMed ID: 16042896
[No Abstract] [Full Text] [Related]
7. Hepatitis B surface antigen seroclearance during chronic HBV infection.
Chu CM; Liaw YF
Antivir Ther; 2010; 15(2):133-43. PubMed ID: 20386068
[TBL] [Abstract][Full Text] [Related]
8. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B.
Lau GK; Cooksley H; Ribeiro RM; Powers KA; Shudo E; Bowden S; Hui CK; Anderson J; Sorbel J; Mondou E; Rousseau F; Lewin S; Perelson AS; Locornini S; Naoumov NV
Antivir Ther; 2007; 12(5):705-18. PubMed ID: 17713154
[TBL] [Abstract][Full Text] [Related]
9. [Bringing the antiviral therapy home for chronic hepatitis B patients: host immunity influences the efficacy and disease prognosis].
Wang FS; Zhang JY
Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):164-6. PubMed ID: 19554778
[No Abstract] [Full Text] [Related]
10. Hepatitis B: explosion of new knowledge.
Keeffe EB
Gastroenterology; 2007 Nov; 133(5):1718-21. PubMed ID: 17983813
[No Abstract] [Full Text] [Related]
11. Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients.
Kwak MS; Cho EJ; Jang ES; Lee JH; Yu SJ; Kim YJ; Yoon JH; Lee HS
Digestion; 2011; 84 Suppl 1():23-8. PubMed ID: 22156482
[TBL] [Abstract][Full Text] [Related]
12. Spontaneous hepatitis B surface antigen seroclearance confers appreciably high rates except in patients with relapse of hepatitis.
Xin YN; Xuan SY
Hepatology; 2008 Sep; 48(3):1021-2; author reply 1022. PubMed ID: 18756479
[No Abstract] [Full Text] [Related]
13. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
[TBL] [Abstract][Full Text] [Related]
14. Chronic hepatitis B infection in pregnancy illustrated by a case of successful treatment with entecavir.
Kakogawa J; Sakurabashi A; Sadatsuki M; Gomibuchi H; Minoura S
Arch Gynecol Obstet; 2011 Dec; 284(6):1595-6. PubMed ID: 21861151
[No Abstract] [Full Text] [Related]
15. Chronic HBV without e antigen: using HBV DNA to guide management.
Tran T; Martin P
Am J Gastroenterol; 2003 Oct; 98(10):2115-7. PubMed ID: 14572554
[No Abstract] [Full Text] [Related]
16. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection.
Liu J; Lee MH; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; Wang LY; You SL; Hsiao CK; Yang HI; Chen CJ
J Hepatol; 2013 May; 58(5):853-60. PubMed ID: 23246508
[TBL] [Abstract][Full Text] [Related]
17. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
Seto WK; Wong DK; Fung J; Huang FY; Lai CL; Yuen MF
Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K
J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
[TBL] [Abstract][Full Text] [Related]
19. HBV Chronic hepatitis during chemotherapy - an immune controlled disease.
Caruntu FA; Gheorghita V
J Gastrointestin Liver Dis; 2008 Dec; 17(4):445-9. PubMed ID: 19104707
[No Abstract] [Full Text] [Related]
20. Measuring immunity in viral hepatitis.
Kanto T; Hayashi N
J Gastroenterol; 2004 Aug; 39(8):709-16. PubMed ID: 15338363
[No Abstract] [Full Text] [Related]
[Next] [New Search]
